AngelaGoffredo(King)FleischmanMDPhD
Hematology • Orange, CAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Associate Professor
Dr. Fleischman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 The City Dr S
Orange, CA 92868Phone+1 949-999-2400
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2007 - 2011- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2005 - 2007
Stanford University School of MedicineClass of 2005
Certifications & Licensure
OR State Medical License 2013 - Present
CA State Medical License 2013 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Start of enrollment: 2014 Jul 08
- A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Start of enrollment: 2018 Jan 26
- The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase Start of enrollment: 2018 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsCigarette smoke stimulates clonal expansion of Jak2and Tet2cells.Gajalakshmi Ramanathan, Jane H Chen, Nitya Mehrotra, Tiffany Trieu, Aaron Huang
Frontiers in Oncology. 2023-01-01 - 412 citationsOncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CMLJulia E. Maxson, Jason Gotlib, Daniel A. Pollyea, Angela G. Fleischman, Anupriya Agarwal
The New England Journal of Medicine. 2013-05-08 - 36 citationsKey Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.Laura F. Mendez Luque, Amanda L. Blackmon, Gajalakshmi Ramanathan, Angela G. Fleischman
Current Hematologic Malignancy Reports. 2019-06-01
Journal Articles
- Inhibition of Interleukin-1 Receptor-Associated Kinase 1 (IRAK1) as a Therapeutic StrategyAngela Fleischman, John O. Mascarenhas, Jack W. Singer, Oncotarget
Abstracts/Posters
- JAK2V617F Hematopoietic Stem and Progenitors Are More Resistant to Chronic Blockage of IL-10 Signaling in a Murine Model of Myeloproliferative NeoplasmsAngela G. Fleischman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center DatabaseAngela G. Fleischman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Myeloproliferative Neoplasms Roundtable: How Will We Cure Myelofibrosis?60th American Society of Hematology Annual Meeting - 12/3/2018
- N-Acetylcysteine As a Therapeutic for JAK2V617F Myeloproliferative Neoplasms2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
The Importance of Developing Open Communication and a Professional, Long-Term Relationship Between Patients with Chronic Myeloid Leukemia and Their OncologistMay 23rd, 2023
CURE Media Group Announces the 2018 MPN Heroes®November 30th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
